Last reviewed · How we verify

Methylcellulose Gel

Maha Zuhair · FDA-approved active Small molecule Quality 5/100

Methylcellulose Gel is a Small molecule drug developed by Maha Zuhair. It is currently FDA-approved.

Methylcellulose Gel, marketed by Maha Zuhair, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its well-established mechanism of action. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameMethylcellulose Gel
SponsorMaha Zuhair
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylcellulose Gel

What is Methylcellulose Gel?

Methylcellulose Gel is a Small molecule drug developed by Maha Zuhair.

Who makes Methylcellulose Gel?

Methylcellulose Gel is developed and marketed by Maha Zuhair (see full Maha Zuhair pipeline at /company/maha-zuhair).

What development phase is Methylcellulose Gel in?

Methylcellulose Gel is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing